Debbie Goldschmidt
New York
Education
Ph.D., economics, Boston University; M.A., economics, Universitat Pompeu Fabra; B.A., mathematics, University of Pennsylvania
Summary of Experience
Dr. Goldschmidt is an economist who specializes in the application of statistics and econometrics to health economics and outcomes research (HEOR). Her work includes medical chart reviews, retrospective claims analyses, physician surveys, surveys of the general public, and clinical trial analyses. Dr. Goldschmidt has conducted research in a range of disease areas, including oncology, neurology, and immunology. Her research has been published in peer-reviewed journals and presented at clinical and health economics research conferences. Prior to joining Analysis Group, Dr. Goldschmidt worked at two financial services firms.
Selected Publishing
-
Direct health care costs associated with COVID-19 in the United States
Journal of Managed Care & Specialty Pharmacy, 2022
2022DeMartino J, Swallow E, Goldschmidt D, Yang K, Viola M, Radtke T, Kirson N
-
Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial
Arthritis Research & Therapy, 2022
2022Bergman M, Tundia N, Martin N, Suboticki JL, Patel J, Goldschmidt D, Song Y, Wright GC
-
Burden of illness for patients with cholangiocarcinoma in the United States: a retrospective claims analysis
Journal of Gastrointestinal Oncology, 2021
2021Chamberlain CX, Faust E, Goldschmidt D, Webster N, Boscoe AN, Macaulay D, Linton Peters ML
-
Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY
Rheumatology, 2020
2020Strand V, Tundia N, Wells A, Buch MH, Radominski SC, Camp HS, Friedman A, Suboticki JL, Dunlap K, Goldschmidt D, Bergman M
-
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
Arthritis Research & Therapy, 2019
2019Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M
-
Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer
Advances in Therapy. 2018 Aug;35(8):1251-1264
2018Guérin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA
-
Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
Advances in Therapy. 26 Mar 2018:1-12
2018Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, Guerin A, Gauthier G, Wu EQ, Niravath P, Small T
News
-
March 3, 2023
-
February 13, 2023
-
July 11, 2022
-
June 4, 2021